{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-019747","form_type":"8-K","ticker":"MNPR","cik":"0001645469","company_name":"Monopar Therapeutics","filed_at":"2024-06-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.407699+00:00","generated_at":"2026-06-01T05:18:37.968119+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Monopar presents preclinical uPAR-targeted radiopharma data at SNMMI; Phase 1 trial ongoing","bullets":["Data show robust tumor uptake of MNPR-101-Zr in triple-negative breast, colorectal, and pancreatic cancer mouse models.","Construct optimized for higher tumor uptake and stability with minimal bone and healthy tissue accumulation.","First-in-human Phase 1 imaging/dosimetry trial in advanced cancer patients recently initiated led by Prof. Rodney Hicks.","Trial details available on ClinicalTrials.gov under identifier NCT06337084."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-019747","json":"https://secwatch.observer/filing/0001437749-24-019747.json","markdown":"https://secwatch.observer/filing/0001437749-24-019747.md","text":"https://secwatch.observer/filing/0001437749-24-019747.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1645469/000143774924019747/0001437749-24-019747-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1645469/000143774924019747/mnpr20240608c_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T05:18:37.968119+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}